Michael Mooney, MD
Interventional Cardiology · Minneapolis, MNNPI 1619931847
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Medtronic accounts for 67.3% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2020 at $8,072 and has fallen 99.1% since, to $70 in 2025.
Across 47 payments — averaging $541.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$17K
- Acist Medical Systems, Inc.$7K
- Abbott$1K
- Boston Scientific$108
- Angiodynamics, Inc.$38
- Penumbra, Inc.$29
What the payments were for
- Consulting fees$13,12552%
- Speaking & faculty fees$7,85031%
- Travel & lodging$2,76611%
- Food & beverage$1,7307%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 32 | $17,140 |
| Acist Medical Systems, Inc. | 4 | $6,963 |
| Abbott | 4 | $1,192 |
| Boston Scientific | 4 | $108 |
| Angiodynamics, Inc. | 2 | $38 |
| Penumbra, Inc. | 1 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Resolute$8,830
- COREVALVE EVOLUT R$7,161
- Devices$6,500
- HeartMate 3 Left Ventricular Assist Device$1,050
- CVI SYSTEMS$463
How this compares
$25,471 in reported general payments places this provider in the 75th percentile of 84 interventional cardiology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 84 | $95,505 |
| EntrestoSacubitril/Valsartan | 33 | $46,355 |
| FarxigaDapagliflozin Propanediol | 31 | $28,732 |
| XareltoRivaroxaban | 16 | $24,803 |
| JardianceEmpagliflozin | 12 | $12,725 |
| Repatha SureclickEvolocumab | 13 | $10,534 |
| Metoprolol Succinate | 114 | $1,839 |
| Torsemide | 46 | $1,175 |
| Rosuvastatin Calcium | 86 | $1,135 |
| Atorvastatin Calcium | 77 | $1,029 |
| Losartan Potassium | 87 | $676 |
| Furosemide | 72 | $426 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 28 | $397 |
| Carvedilol | 43 | $316 |
| Spironolactone | 32 | $249 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Minneapolis
- Emmanouil BrilakisMinneapolis$548K
- Wesley PedersenMinneapolis$493K
- Michael ManolesMinneapolis$201K
- Jay TraverseMinneapolis$198K
- Robert WilsonMinneapolis$176K
- Yale WangMinneapolis$168K
- Steven RohMinneapolis$67K
- Stefan BertogMinneapolis$64K
- Konstantinos VoudrisMinneapolis$46K
- Alok SharmaMinneapolis$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.